Journal
CELL REPORTS
Volume 21, Issue 1, Pages 195-207Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2017.09.021
Keywords
-
Categories
Funding
- NIH [R01AR050772]
- Cancer Prevention and Research Institute of Texas [RP130078]
- Department of Defense [W81XWH-16-1-0100]
- Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2016R1A6A3A11933284]
- Arthritis Foundation of the United States [6128]
- National Research Foundation of Korea [2016R1A6A3A11933284] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Th17 cells are potent mediators in autoimmune diseases, and RORgt is required for their development. Recent studies have shown that ROR gamma t(+) Treg cells in the gut regulate intestinal inflammation by inhibiting effector T cell function. In the current study, we report that ROR gamma t(+) Treg cells were also found in lymph nodes following immunization. Not only distinct from intestinal ROR gamma t(+) Treg cells in their transcriptomes, peripheral ROR gamma t(+) Treg cells were derived from Foxp3(+) thymic Treg cells in an antigen-specific manner. Development of these ROR gamma t(+) Treg cells, coined T regulatory 17 (Tr17) cells, depended on IL-6/Stat3 signaling. Tr17 cells showed suppressive activity against antigen-specific effector T cells in vitro. In addition, Tr17 cells efficiently inhibited myelin-specific Th17-cell-mediated CNS auto-inflammation in a passive EAE model. Collectively, our study demonstrates that Tr17 cells are effector Treg cells that potentially restrict autoimmunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available